CRISPR gene editing of angiopoietin-like 3: toward one-time precision therapy for dyslipidaemia

In a landmark study published in The New England Journal of Medicine, Laffin et al.¹ present the first-in-human clinical evaluation of CTX310, an investigational in vivo CRISPR–Cas9 therapy engineered to induce permanent loss-of-function mutations in the hepatic ANGPTL3 gene, resulting in sustained lowering of atherogenic lipoproteins. This marks a major step toward durable, potentially lifelong lipid lowering through a single therapeutic intervention,¹ potentially replacing years of ongoing lipid-lowering treatment for atherosclerotic cardiovascular disease (ASCVD) patients.

ASCVD remains the leading cause of mortality worldwide. Although therapies such as statins, PCSK9 inhibitors, and emerging siRNA or antisense-based agents, have expanded the lipid-lowering repertoire; many patients still fail to achieve adequate LDL reduction or continue to exhibit elevated triglycerides. In this context, therapies targeting angiopoietin-like protein 3 (ANGPTL3), a hepatically secreted inhibitor of lipoprotein lipase (LPL) and endothelial lipase, has emerged as a compelling therapeutic target.² Individuals with natural loss-of-function variants in ANGPTL3 display profoundly reduced triglycerides and LDL cholesterol, along with markedly lower ASCVD risk and no apparent adverse consequences.² This has positioned ANGPTL3 as a non-essential yet powerful metabolic node for therapeutic inhibition.

Monoclonal antibodies and RNA-targeted therapeutics directed against ANGPTL3 have confirmed the clinical validity of this target.^2,3 These antibodies act extracellularly by transiently binding circulating ANGPTL3, with effects that diminish as drug levels decline. Such therapies require recurrent dosing, raising concerns about long-term adherence, durability, and cumulative cost. CRISPR-based genome editing, in contrast, offers the prospect of a one-time molecular modification capable of lifelong benefit. These therapies have the potential to disrupt ANGPTL3 at the DNA level, permanently abolishing gene expression and eliminating the possibility of pharmacologic reversal once editing has occurred.

In this Phase 1 A single-ascending-dose trial,¹ 15 adults with refractory hypercholesterolemia or hypertriglyceridemia were enrolled across Australia, New Zealand, and the UK. Participants reflected real-world heterogeneity: 40% had established ASCVD, 40% had familial hypercholesterolemia, and baseline LDL averaged 155 ± 79 mg/dL. All had persistent dyslipidemia despite maximal therapy, underscoring the need for alternative interventions.

CTX310 was administered as a single intravenous infusion (0.1–0.8 mg/kg) and showed a reassuring early safety profile. No dose-limiting toxicities or serious treatment-related events occurred. One unrelated death occurred months after the lowest dose, without preceding clinical or laboratory abnormalities during extended follow-up. The absence of early infusion reactions, delayed immune signals, or evolving systemic symptoms argues against LNP-related toxicity or idiosyncratic immune responses. Overall, the safety signals compare favourably with those of other in vivo gene-editing and LNP-based modalities.

Participants receiving the highest doses exhibited robust reductions in ANGPTL3 protein levels and corresponding lipid improvements within 60 days: LDL cholesterol decreased by up to 48.9%, triglycerides by 55.2%, and non-HDL lipoproteins by similar margins. The magnitude of LDL reduction approximates that seen with the ANGPTL3 monoclonal antibody evinacumab, while offering the potential for permanence.⁴ Particularly noteworthy is the dual lowering of LDL and triglycerides, a rarity among existing lipid-lowering modalities. By simultaneously relieving ANGPTL3-mediated inhibition of lipases, gene editing appears to unlock a broader spectrum of metabolic benefits than most single-pathway drugs.

For patients genetically predisposed to hypercholesterolemia or with severe hypertriglyceridemia, durable ANGPTL3 suppression could meaningfully reduce lifelong ASCVD risk, especially for those unresponsive to current therapies. Moreover, poor adherence to chronic lipid-lowering medications is a well-documented challenge: nearly half of patients discontinue statins within a year of initiation.⁵ A one-time therapy bypasses the adherence barrier entirely, providing sustained metabolic control regardless of patient behaviour or healthcare access.

However, enthusiasm must be tempered with appropriate scientific and regulatory caution. First, the sample size remains very small, and follow-up is limited to the early post-treatment period. Durability, hepatotoxicity profiles, immune activation, low-frequency off-target edits, and potential pro-oncogenic consequences may only manifest years after the initial intervention. These risks are particularly salient in the liver, where injury, regeneration, and clonal hepatocyte repopulation can amplify rare mutational events. Consistent with regulatory precedent for gene-editing therapies, extended safety monitoring—including serial genomic analyses and long-term clinical adjudication—will be essential.

Second, efficacy varied among participants, likely reflecting differences in hepatic steatosis, inflammatory status, LNP uptake pathways, and germline variation in lipid metabolism which all shape both editing efficiency and downstream lipoprotein handling. Integrative analyses that combine quantitative imaging of steatosis, inflammatory biomarkers, liver-derived transcriptomic or epigenomic signatures, and genetic modifiers of ANGPTL3 responsiveness will be important in clarifying sources of heterogeneity. Currently, genomic monitoring is optimized to detect on-target modification and higher-frequency off-target events using bulk sequencing approaches. However, these methods have limited sensitivity for rare, cell-restricted, or spatially localized edits within the liver. In steatotic or inflamed hepatic tissue—where injury, regeneration, and clonal hepatocyte expansion may occur—such low-frequency events could acquire biological relevance over time. Addressing this limitation will likely require the incorporation of ultra-deep sequencing and longitudinal sampling strategies. Such tools will directly inform dose optimization, patient stratification, and potentially the development of delivery systems tailored to diseased hepatic microenvironments.

A broader question concerns how a one-time ANGPTL3 edit should be positioned clinically. Its irreversible nature confers unprecedented durability but demands precise patient selection. Should this modality be limited to individuals with severe monogenic dyslipidemias? Offered after insufficient response to current therapies? Or considered earlier in the treatment cascade, where a single definitive intervention could overcome adherence limitations that undermine long-term lipid management? Comparative-effectiveness research, lifetime cardiovascular risk modeling, and rigorous cost-effectiveness analyses will be required to define its eventual place in practice and determine whether permanent editing can compete with or complement existing chronic therapies. As safety, specificity, and delivery are optimized, in vivo editing may become a cornerstone of future cardiometabolic medicine.

In summary, Laffin et al. provide compelling early evidence that a single infusion of an in vivo CRISPR–Cas9 therapy can safely and substantially reduce atherogenic lipoproteins in humans. While long-term follow-up and larger population studies remain essential, these results demonstrate the feasibility of one-time gene editing as a durable strategy for lipid-lowering and ASCVD prevention. CTX310 represents an exciting step toward precision genome-based cardiometabolic therapy and underscores the transformative potential of CRISPR technologies as they move from rare diseases toward broadly prevalent conditions. This study marks the beginning of a new era in cardiometabolic medicine, one where genotype-level correction, rather than chronic pharmacologic suppression, may define long-term disease prevention. The challenge now is to translate this remarkable proof of concept into a reliable, safe, and equitable therapeutic reality.